- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | CARSGEN-B (02171): INTERIM REPORT 2025 | 1 | HKEx | ||
| 04.09. | CARSGEN-B (02171): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | - | HKEx | ||
| 15.08. | CARsgen Therapeutics Holdings reports H1 results | 2 | Seeking Alpha | ||
| 15.08. | CARsgen Therapeutics Announces 2025 Interim Results | 437 | PR Newswire | SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 14.08. | CARSGEN-B (02171): ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT ... | 2 | HKEx | ||
| 01.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 25.07. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 1 | HKEx | ||
| 22.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL FOR ADJUVANT THERAPY OF PANCREATIC CANCER ACCEPTED FOR POSTER PRESENTATION ... | 2 | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL ... | 2 | HKEx | ||
| 16.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON CT071 AT 2025 EHA ANNUAL CONGRESS | 3 | HKEx | ||
| 02.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON SATRI-CEL IN THE LANCET AND AT THE 2025 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 28.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SATRICABTAGENE AUTOLEUCEL GRANTED PRIORITY REVIEW BY THE NMPA | 1 | HKEx | ||
| 22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2025 | - | HKEx | ||
| 13.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 2 | HKEx | ||
| 12.05. | CARsgen Therapeutics: CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy | 416 | PR Newswire | SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 29.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT071 ACCEPTED FOR POSTER PRESENTATION AT 2025 EHA ANNUAL CONGRESS | 1 | HKEx | ||
| 16.04. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME | 1 | HKEx | ||
| 16.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 16.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 16.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 2 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.